News Allergan ‘not looking for big deals’ as growth slows Company will put its $27 billion to use, however
News Merck, Allergan named as potential bidders for Biogen Biogen vulnerable to takeover as chief executive steps down
News NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with ATTR polyneuropathy
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
